Pharmacogenomics of platinum-based chemotherapy in NSCLC
about
Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancerGenome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapyGenetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancerMultiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patientsMeta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients.BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysisMcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response.Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?On the pharmacogenetics of non-small cell lung cancer treatment.Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism.The Ku70 -1310C/G promoter polymorphism is associated with breast cancer susceptibility in Chinese Han population.Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].The (CCTTT)n microsatellite polymorphism in the NOS2 gene may influence lung cancer risk and long-term survival, especially in non-smokers
P2860
Q26863490-5392349D-9BE9-4925-A6FD-2B9B8720A268Q28943514-F2F9EAF1-F7E4-48A2-9153-D237BA614067Q33940693-1179D552-8852-4004-8450-B069B614084CQ34177673-52FE2DDA-B768-40F4-82B5-C8F5154588ABQ34325669-FBA0BD6C-B09D-4439-A666-887B50C65DE3Q35041187-0AAFD9B4-5A67-46D4-97D7-9CF75D206858Q36085960-22367783-3579-49ED-8528-65C23BE8074EQ36698880-51239087-904E-42A4-A93D-DA5E4768BB95Q37688183-2B2A6E78-5DE9-480B-BEC0-01356C9C6BBFQ37688309-703C2BCB-432C-4245-BD1A-9B253194ED11Q37707092-35B4F7B4-DD95-4B7B-9516-6FDDC63BF6EDQ37730044-B183F1C9-FA6D-42BC-B53E-13D3A8CD3225Q37978771-A95D94B0-698F-49DF-8113-603077D23985Q38030053-FFE3F299-0E87-4519-902A-C568957A6BDEQ38694947-55841A92-EB62-45C2-B024-111064B5C8CFQ38953629-6C7B4B95-D8E1-41BE-A5B8-B3F3CCA13BD7Q39015690-8F7D02E7-7434-4E21-BDDC-38656CDB3C59Q39253575-292A55F8-CE06-4938-98D7-2D18EAA712FCQ40691174-F2AB4246-FFFA-470A-9915-0B7EC5DCEA87Q42353453-44409B7F-E6C3-4133-8AFD-0038EC16E762Q42740112-B3B9F861-C412-4281-AD84-09B893ABCF32Q44783785-ECDAD87D-7443-4BF8-BE19-E590B003F3B4Q47309064-F25DE22E-C69C-44D7-A8BB-1EA6ADFF48CAQ54334971-49613359-F494-4F70-B499-2A6FD3CCAA42Q57011093-DBCBBB8C-7FBE-4D55-BCC6-D9D73FC09460
P2860
Pharmacogenomics of platinum-based chemotherapy in NSCLC
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@ast
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@en
type
label
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@ast
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@en
prefLabel
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@ast
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@en
P2860
P1476
Pharmacogenomics of platinum-based chemotherapy in NSCLC
@en
P2093
Michelle A T Hildebrandt
P2860
P304
P356
10.1517/17425250902973711
P407
P50
P577
2009-07-01T00:00:00Z